Pharmaceutical industry – Page 4
-
BusinessDanaher completes $5.7 billion Abcam acquisition
Deal proceeded despite significant opposition from founder and ex-chief Jonathan Milner
-
BusinessLife-saving cancer gene therapy under investigation after being linked to rare secondary cancers
US drug agency examining six CAR-T therapies after reports of T-cell malignancies
-
OpinionCompounding problems
Regulating the line between a vital service and grey-market profiteering is a mess
-
BusinessUK becomes first country in the world to authorise a Crispr-based gene therapy
Treatment aims to cure patients with β-thalassaemia and sickle-cell disease
-
BusinessWeight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments
-
OpinionSlow march of the retrosynthesis robots
Software synthesis suggestions are hampered by biased and incomplete datasets
-
BusinessBuilding the support infrastructure we wish we’d had
Harry Destecroix of Science Creates is the 2023 Chemistry World Entrepreneur of the Year
-
BusinessUS regulator says phenylephrine is ineffective as a decongestant
FDA will begin consultation on removing the drug from hundreds of over-the-counter remedies
-
-
BusinessAddressing the saga of nitrosamine contamination in drugs
Scientific and regulatory progress is helping minimise the impact of mutagenic impurities
-
BusinessPositive trial sets stage for therapeutic use of MDMA in US
Hallucinogen-assisted psychiatric treatment heads to regulators, amid cost and other concerns
-
BusinessTornado at Pfizer plant accentuates US drug shortage issues
Perennial problem will not be addressed without major reforms to drug market
-
FeatureThe drug developers fighting the antibiotic resistance problem
Andy Extance talks to the researchers innovating across different drug classes in the hunt to develop new treatments
-
OpinionResistant to change
Curbing industrial practices that drive antimicrobial resistance needs tighter regulation and enforcement
-
BusinessHow can we maintain the effectiveness of existing antimicrobials?
Reducing environmental pollution and tackling quality issues to stave off resistance
-
FeatureWho will pay for new antibiotics?
Governments around the world are starting to consider alternative funding models and incentives for antibiotics. Katrina Megget asks if it is enough
-
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
-
FeatureCharting the rise in antimicrobial resistance
We look at the data behind antibiotic drug discovery and development, bacterial resistance and the financial problems with the current business model
-
ArticleCPHI Barcelona 2023: forging collaborations for a promising future in the pharmaceutical sector
CPHI creates connections and inspires partnerships across the global pharma community
-
OpinionCould cheap CRO rates threaten to destabilise biotech?
Pharmaceutical pipelines are heavily dependent on contract research organisations; we can’t afford for them to fail